News

Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform.

“Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.”

Announcement_Graphics_FB_1200x630.jpg

This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples.

“Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.”

Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors.

Read more here.

“We are very happy with our investment in Ceres and are pleased that Streck has joined us,” said Tom Miller, GreyBird Ventures Co-Founder and Chair of Ceres’ Board. “A world-class company like Streck as a strategic partner, coupled with a Ceres team that has demonstrated the ability to solve some of the most difficult problems in health care diagnostics, is a clear catalyst for accelerated growth.”

Recent News

02/29/2024

VCU Health leads clinical trial for new treatment to help people with bowel control problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels. The implantation surgery for the clinical trial

02/22/2024

Don’t Miss These Spring Talent Events

We’ve compiled a calendar of events happening this spring aimed at connecting talented people in the biosciences. Feb. 27: Internship Support for Employers: V-TOP Staffing Agency + Matching Funds | Virtual Employers can tune in to learn more internship support through V-TOP’s partnership with iQuasar, the statewide staffing agency and how to utilize their matching funds

02/21/2024

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.